Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts
December 18, 2025 — Insmed Incorporated (NASDAQ: INSM) shares dropped sharply Thursday after the company disclosed a Phase 2b setback for brensocatib in a chronic sinus condition and said it is discontinuing development in that indication, even as it simultaneously